{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:27:31Z","timestamp":1762882051930,"version":"3.45.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10384-025-01235-x","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T23:10:16Z","timestamp":1750461016000},"page":"932-937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reconsideration of conversion to multiple sclerosis: one-year cerebral lesion appearance rate of Japanese aquaporin-4 antibody-negative optic neuritis patients"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7199-6111","authenticated-orcid":false,"given":"Satoshi","family":"Ueki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhisa","family":"Hatase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Fukuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"1235_CR1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"key":"1235_CR2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","volume":"21","author":"A Petzold","year":"2022","unstructured":"Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022;21:1120\u201334.","journal-title":"Lancet Neurol"},{"key":"1235_CR3","first-page":"727","volume":"65","author":"Optic Neuritis Study Group","year":"2008","unstructured":"Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727\u201332.","journal-title":"Arch Neurol"},{"key":"1235_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennet JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology"},{"key":"1235_CR5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/milmed\/usab352","volume":"188","author":"W Gu","year":"2023","unstructured":"Gu W, Tagg NT, Panchal NL, Brown-Bickerstaff CA, Nyman JM, Reynolds ME. Incidence of optic neuritis and the associated risk of multiple sclerosis for service members of U.S. Armed Forces. Mil Med. 2023;188:697\u2013702.","journal-title":"Mil Med."},{"key":"1235_CR6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/WNO.0000000000001700","volume":"43","author":"AM Kruszewski","year":"2023","unstructured":"Kruszewski AM, Tauqeer Z, Meer EA, Bautista SA, Cherayil NR, Cimino ME, et al. Vision loss as a presenting feature of chronic inflammatory demyelinating polyneuropathy: a case series. J Neuroophthalmol. 2023;43:48\u201354.","journal-title":"J Neuroophthalmol"},{"key":"1235_CR7","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.3390\/jcm10214970","volume":"10","author":"K Fukuda","year":"2021","unstructured":"Fukuda K, Mizobuchi T, Nakajima I, Kishimoto T, Miura Y, Taniguchi Y. Ocular involvement in relapsing polychondritis. J Clin Med. 2021;10:4970.","journal-title":"J Clin Med"},{"key":"1235_CR8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","volume":"77","author":"A Kunchok","year":"2020","unstructured":"Kunchok A, Akamit AJ, Davis JM 3rd, Kantarci OH, Keegan BM, Pittock SJ, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020;77:937\u201346.","journal-title":"JAMA Neurol"},{"key":"1235_CR9","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207805","volume":"102","author":"A Vidal-Jordana","year":"2024","unstructured":"Vidal-Jordana A, Rovira A, Calderon W, Arrambide G, Castill\u00f3 J, Moncho D, et al. Adding the optic nerve in multiple sclerosis diagnostic criteria. Neurology. 2024;102: e200805.","journal-title":"Neurology"},{"key":"1235_CR10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10384-021-00858-0","volume":"65","author":"S Ueki","year":"2021","unstructured":"Ueki S, Hatase T, Kiyokawa M, Kawachi I, Saji E, Onodera O, et al. Visual outcome of aquaporin-4 antibody-positive optic neuritis with maintenance therapy. Jpn J Ophthalmol. 2021;65:699\u2013703.","journal-title":"Jpn J Ophthalmol"},{"key":"1235_CR11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","volume":"126","author":"H Ishikawa","year":"2019","unstructured":"Ishikawa H, Kezuka T, Shikishima K, Yamagami A, Hiraoka M, Chuman H, et al. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology. 2019;126:1385\u201398.","journal-title":"Ophthalmology"},{"key":"1235_CR12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41582-024-01005-2","volume":"20","author":"R Geraldes","year":"2024","unstructured":"Geraldes R, Arrambide G, Banwell B, Rovira \u00c0, Cortese R, Lassmann H, et al. The influence of MOGAD on diagnosis of multiple sclerosis using MRI. Nat Rev Neurol. 2024;20:620\u201335.","journal-title":"Nat Rev Neurol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01235-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:21:45Z","timestamp":1762881705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01235-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01235-x","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"type":"print","value":"0021-5155"},{"type":"electronic","value":"1613-2246"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Ueki, None; Y. Hasegawa, None; T. Hatase, None; I. Kawachi, funding for research, travel, and\/or speaker\u2019s honoraria (Chugai, Novartis, Biogen, Alexion, Mitsubishi Tanabe, Takeda, Teijin, Argenx, Daiichi-Sankyo), scientific advisory board member (Mitsubishi Tanabe, Chugai); T. Fukuchi, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}